What Researchers Did
Researchers retrospectively reviewed data from 56 patients with moderate idiopathic sudden sensorineural hearing loss (ISSNHL) who received either corticosteroid, hyperbaric oxygen (HBO2), or a combination of both, in addition to intravenous vasodilator treatment.
What They Found
All three treatment groups showed a similar recovery rate, with an effective rate exceeding 50% and an average hearing gain of 17.38 decibels (dB). While hyperbaric oxygen (HBO2) treatment alone resulted in a higher recovery rate, the combination therapy of corticosteroid and HBO2 did not further improve the recovery rate.
What This Means for Canadian Patients
Canadian patients experiencing moderate idiopathic sudden sensorineural hearing loss (ISSNHL) may find hyperbaric oxygen (HBO2) therapy to be a beneficial treatment option. They should discuss the potential role of HBO2, either alone or in combination with corticosteroids, with their healthcare providers to determine the most suitable treatment plan.
Canadian Relevance
This study has no direct Canadian connection or specific relevance to the Canadian healthcare system.
Study Limitations
As a retrospective study with a relatively small sample size of 56 patients, this research may be subject to selection bias and other confounding factors.